menu ☰
menu ˟

Pembrolizumab reduces recurrence risk in stage III melanoma

15 Apr 2018
Alexander M.M. EggermontCHICAGO — Patients with stage III melanoma at high risk for recurrence after surgery demonstrated significantly reduced risk for recurrence after 1 year of treatment with pembrolizumab, according to results from the KEYNOTE-...

Click here to view the full article which appeared in Hematology Oncology

IPH Logo